14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AUTL vs EVMN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Autolus Therapeutics plc American Depositary Share (AUTL) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). AUTL carries a Unified Composite Score of 40.4/100 (SELL) at $1.14 (N/M Forward P/E, -159.3% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While AUTL currently prints a higher short-term Unified Composite Score (40.4/100 SELL vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -159.3% operating margin) and revenue trajectory (+0.0% vs. +94.6% YoY).
Defensive Composite Rating Caution: Although EVMN compares more favorably head-to-head, both AUTL (40.4/100 SELL) and EVMN (30.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: AUTL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.2); meanwhile EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AUTL vs EVMN. Trailing 12-month operating profitability (AUTL -159.3% vs EVMN 0.0%) and valuation multiples (AUTL N/M vs EVMN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AUTL vs EVMN Key Questions & Quantitative Answers
As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Autolus Therapeutics plc American Depositary Share (AUTL) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). AUTL carries a Unified Composite Score of 40.4/100 (SELL) at $1.14 (N/M Forward P/E, -159.3% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AUTL currently prints a higher short-term Unified Composite Score (40.4/100 SELL vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -159.3% operating margin) and revenue trajectory (+0.0% vs. +94.6% YoY). Defensive Composite Rating Caution: Although EVMN compares more favorably head-to-head, both AUTL (40.4/100 SELL) and EVMN (30.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: AUTL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.2); meanwhile EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AUTL leads the Growth & Scale pillar: AUTL posts +94.6% YoY revenue growth and +0.0% YoY earnings growth on $137M TTM revenue (-45.0% gross margin, -159.3% operating margin), compared with EVMN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AUTL generates $137M in USD-normalized revenue versus N/A for EVMN. In operating R&D and SG&A reinvestment, AUTL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVMN.
AUTL screens cheaper on headline valuation multiples. AUTL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (unreported EBITDA margin), whereas EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AUTL (-174.9% ROE) versus EVMN (-69.5% ROE) capital efficiency.
In options market volatility and institutional positioning, AUTL carries 90.0% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.66β · 55% Vol realized risk). By comparison, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.